Saniona (SANION) Life Science Conference 2026 summary

Strategic partnerships and financial highlights

• Secured major licensing and collaboration deals with Acadia and Jazz, totaling $1.6 billion in potential value and generating $700 million in upfront payments over two years.

• Maintains a strong financial position with DKK 580 million in cash at year-end and DKK 820 million available for internal development, supported by upcoming milestones.

• Plans to leverage a sale-leaseback of headquarters to further strengthen liquidity.

• Non-dilutive income streams from partnerships and potential royalties from regulatory approvals in other markets.

R&D pipeline and clinical development

• Focused on CNS diseases with a validated ion channel drug discovery platform, enabling both internal and partnered product development.

• Internal pipeline targets epilepsy and treatment-resistant depression, addressing significant unmet needs.

• Lead compounds include SAN2668 for severe pediatric epilepsies, SAN2465 for major depressive disorders, and SAN2219 for refractory focal onset seizures.

• All three candidates are entering phase I clinical studies, with two starting by year-end and one in early 2027.

Differentiation and competitive positioning

• SAN2668 shows high efficacy similar to benzodiazepines but with fewer side effects, targeting developmental epileptic encephalopathies in children.

• SAN2465 offers rapid onset for depression with a safer profile than esketamine.

• SAN2219 is positioned for adult focal onset seizures, showing strong efficacy without sedation.

• PET ligands and quantitative EEG biomarkers will support dose selection and differentiation in clinical trials.